Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A4-specific TCR-T cells (Sun Yat-Sen Memorial Hospital)
- Development stage
- Unknown
- Lead developer
- Sun Yat-Sen Memorial Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MAGE-A4-specific TCR-T cells (Sun Yat-Sen Memorial Hospital) is an autologous T-cell receptor (TCR) engineered T-cell therapy designed to target the Melanoma-associated antigen A4 (MAGE-A4). MAGE-A4 is a cancer-testis antigen that is frequently overexpressed in various solid tumors, particularly mesenchymal malignancies such as synovial sarcoma and myxoid/round cell liposarcoma, while its expression in normal tissues is restricted to the testis and placenta. The therapy involves harvesting a patient's T cells, genetically engineering them to express a TCR specific for a MAGE-A4 peptide presented by HLA-A*02:01, and expanding them ex vivo before re-infusion. This approach leverages the patient's immune system to specifically recognize and eliminate MAGE-A4-positive cancer cells. It is currently being investigated in a Phase 1 clinical trial for patients with advanced mesenchymal malignancies.
- Other names
- Autologous TCR-T cells targeting MAGE-A4MAGE-A4 TCR-TMAGE-A-4 TCR-TMAGE-A 4 TCR-T
02
Targets
CD8A (T-cell surface glycoprotein CD8 alpha chain)MAGE-A4 peptide-HLA-A*02:01 complex
Beyond the preview
Go deeper on MAGE-A4-specific TCR-T cells (Sun Yat-Sen Memorial Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A4-specific TCR-T cells (Sun Yat-Sen Memorial Hospital).